Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

By sjmartinez • September 2, 2022

Gong J, Thomassian S, Kim S, Gresham G, Moshayedi N, Ye JY, Yang JC, Jacobs JP, Lo S, Nissen N, Gaddam S, Tighiouart M, Osipov A, Hendifar A. Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2022 Sep 2;12(1):15013. doi: 10.1038/s41598-022-19401-3. PMID: 36056179; PMCID: PMC9440135.

Tags: Digestive Diseases, General Internal Medicine, Publications

Related Posts

Corrigendum to “Subchronic inhalation exposure to ultrafine particulate matter alters the intestinal microbiome in various mouse models” [Environ. Res. 248 (2024) 118242]

Chang C, Gupta R, Sedighian F, Louie A, Gonzalez DM, Le C, Cho JM, Park SK, Castellanos J, Ting TW, Dong TS, Arias-Jayo N, Lagishetty[...]

Effectiveness of transoral endoscopic fundoplication with or without hiatal hernia repair in patients with gerd and chronic cough

Swei E, Almario JA, Dunbar K, Yadlapati R, Parker B, Brewer-Gutierrez O, Janu P, Murray M, Sohagia A, Diehl DL, Khara H, Abu Dayyeh B,[...]

Identification of a PRDM1-regulated T cell network to regulate atherosclerotic plaque inflammation

Jin H, Maas SL, Zou Y, Lu C, Yu B, Huchzermeier R, Nadeau S, Dos Santos J, Gijbels M, Mees BME, Smirnov E, Matic L,[...]